DE69838340D1 - Behandlung von neoplasmen mit interferon-empfindlichen, klonalen viren - Google Patents

Behandlung von neoplasmen mit interferon-empfindlichen, klonalen viren

Info

Publication number
DE69838340D1
DE69838340D1 DE69838340T DE69838340T DE69838340D1 DE 69838340 D1 DE69838340 D1 DE 69838340D1 DE 69838340 T DE69838340 T DE 69838340T DE 69838340 T DE69838340 T DE 69838340T DE 69838340 D1 DE69838340 D1 DE 69838340D1
Authority
DE
Germany
Prior art keywords
viruses
neoplasms
interferon
sensitive
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69838340T
Other languages
English (en)
Other versions
DE69838340T2 (de
Inventor
Michael S Roberts
Robert M Lorence
William S Groene
Harvey Rabin
Borstel Reid W Von
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Biologics Corp
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25487533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69838340(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Application granted granted Critical
Publication of DE69838340D1 publication Critical patent/DE69838340D1/de
Publication of DE69838340T2 publication Critical patent/DE69838340T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
DE69838340T 1997-10-09 1998-10-09 Behandlung von neoplasmen mit interferonempfindlichen, klonalen viren Expired - Lifetime DE69838340T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94824497A 1997-10-09 1997-10-09
US948244 1997-10-09
PCT/US1998/021230 WO1999018799A1 (en) 1997-10-09 1998-10-09 Treatment of neoplasms with viruses

Publications (2)

Publication Number Publication Date
DE69838340D1 true DE69838340D1 (de) 2007-10-11
DE69838340T2 DE69838340T2 (de) 2008-05-21

Family

ID=25487533

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838340T Expired - Lifetime DE69838340T2 (de) 1997-10-09 1998-10-09 Behandlung von neoplasmen mit interferonempfindlichen, klonalen viren

Country Status (13)

Country Link
EP (2) EP1032269B1 (de)
JP (3) JP2001519175A (de)
CN (2) CN1281336A (de)
AT (1) ATE371372T1 (de)
AU (1) AU9603898A (de)
CA (1) CA2305269C (de)
DE (1) DE69838340T2 (de)
ES (1) ES2292207T3 (de)
HK (1) HK1028935A1 (de)
HU (1) HUP0003911A3 (de)
IL (1) IL135507A0 (de)
NZ (4) NZ550147A (de)
WO (1) WO1999018799A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
ATE371372T1 (de) * 1997-10-09 2007-09-15 Wellstat Biologics Corp Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
AU4246900A (en) * 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO2000073479A1 (en) * 1999-05-28 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
ES2260057T3 (es) * 1999-09-17 2006-11-01 Wellstat Biologics Corporation Virus oncolitico.
DE19951795A1 (de) * 1999-10-27 2001-05-10 Knebel Doeberitz Magnus Von Verwendung von Parvoviren zur Verbesserung des Allgemeinzustandes bei Tumorpatienten oder Patienten mit chronischen oder konsumierenden Erkrankungen
EP1227828A1 (de) * 1999-11-12 2002-08-07 Oncolytics Biotech, Inc. Viren zur behandlung der zellulären proliferativen erkrankungen
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
CA2412493C (en) 2000-06-26 2010-11-09 Wellstat Biologics Corporation Purging of cells using viruses
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
CN1520303B (zh) * 2001-03-27 2013-04-24 纽约大学 利用基于α病毒且靶向高亲和性层粘连蛋白受体的载体进行肿瘤治疗
ATE500808T1 (de) 2001-05-11 2011-03-15 Wellstat Biologics Corp Onkolytische virustherapie
US20140088177A1 (en) * 2001-07-11 2014-03-27 University Of Miami Recombinant vsv for the treatment of tumor cells
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
EP1944035A1 (de) * 2002-05-09 2008-07-16 Oncolytics Biotech Inc. Verfahren zur Schmerzlinderung durch onkolytische Viren
TR200501460T3 (tr) * 2002-05-09 2005-06-21 Oncolytics Biotech, Inc. Onkolitik virüsler kullanarak ağrı azaltma yöntemi
CN1655827B (zh) 2002-05-27 2010-06-23 佩尔·松内·霍尔姆 腺病毒和编码其的核酸的新应用
AU2003243307B2 (en) * 2002-06-21 2010-04-01 Wellstat Biologics Corporation Administration of therapeutic viruses
EP1578396A4 (de) 2002-08-12 2007-01-17 David Kirn Verfahren und zusammensetzungen gegen pockenviren und krebs
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
MXPA05009526A (es) 2003-03-07 2005-12-15 Robarts Res Inst Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
AU2004289953B2 (en) 2003-06-18 2008-09-25 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
CA2503774C (en) 2003-06-20 2007-09-25 Microbix Biosystems Inc. Improvements in virus production
WO2005014017A1 (ja) 2003-08-08 2005-02-17 Yuji Shino 癌治療用医薬組成物
US20070110719A1 (en) 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
FI20040704A0 (fi) * 2004-05-21 2004-05-21 Ari Hinkkanen Replikatiivisen viruksen tai sen rekombinantin käyttö terapiassa
EP1863906A4 (de) 2005-03-07 2009-06-03 Robarts Res Inst Verwendung einer kombination aus myxoma-virus und rapamycin zur therapeutischen behandlung
US7303898B2 (en) 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
EP1917351A4 (de) 2005-08-01 2009-12-16 Univ Technologies Int Abgeschwächtes reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
CA2621982C (en) 2005-09-07 2017-11-28 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
EP2007883B1 (de) * 2006-04-20 2011-12-28 Wyeth LLC Reinigungsverfahren zur isolierung von gereinigtem vesikulärem stomatitisvirus aus zellkultur
NZ572893A (en) 2006-06-01 2011-06-30 Robarts Res Inst Myxoma virus mutants for cancer treatment
JP5606067B2 (ja) * 2006-09-15 2014-10-15 オタワ ホスピタル リサーチ インスティテュート 腫瘍崩壊性ラブドウイルス
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
EP2202297B1 (de) * 2007-07-18 2014-05-14 Genelux Corporation Verwendung eines chemotherapeutischen Wirkstoffs zur Vorbereitung eines Arzneimittels zur Behandlung oder Milderung der mit oncolytischen Virentherapie verbundenen Nebenwirkungen
CA2699805A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
WO2009143468A1 (en) * 2008-05-22 2009-11-26 Uti Limited Partnership Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy
CA2723587C (en) * 2008-05-27 2017-09-26 Oncolytics Biotech Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
EP2345415B1 (de) * 2008-09-16 2015-01-21 GenomIdea Inc. Therapeutisches/prophylaktisches mittel gegen prostatakrebs
EP2393921B1 (de) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Chimäres newcastle disease virus und seine verwendungen
WO2011032180A1 (en) 2009-09-14 2011-03-17 Jennerex, Inc. Oncolytic vaccinia virus combination cancer therapy
EP2327764B1 (de) * 2009-11-30 2011-12-28 United Cancer Research Institute Neuer Klon des Geflügelpestvirus, Herstellung und Anwendung bei der medizinischen Behandlung von Krebs
AU2012204467B2 (en) 2011-01-04 2016-08-18 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
US20130129678A1 (en) * 2011-11-17 2013-05-23 Zahari Raykov Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer
US20140328798A1 (en) * 2011-11-17 2014-11-06 Deutsches Krebsforschung-Szentrum Co-Administration of a Parvovirus and a Cytokine for Therapy of Pancreatic Cancer
MD4655C1 (ro) 2013-03-14 2020-06-30 Icahn School Of Medicine At Mount Sinai Virusurile bolii de Newcastle şi utilizarea acestora
CA2914790C (en) * 2013-06-14 2024-02-27 Psioxus Therapeutics Limited A dosing regime and formulations for type b adenoviruses
ES2661132T3 (es) 2013-10-25 2018-03-27 Psioxus Therapeutics Limited Adenovirus oncolíticos armados con genes heterólogos
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
MY193281A (en) 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018041838A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
CN1054192A (zh) * 1990-02-26 1991-09-04 张炳团 人体内诱导干扰素的制造方法
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
DZ1706A1 (fr) * 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
FR2699082B1 (fr) * 1993-02-22 1995-05-05 Pasteur Institut Composition pour le traitement de tumeurs et l'immunisation d'organismes à l'encontre de tumeurs.
EP1486211B1 (de) * 1993-04-30 2008-10-22 Wellstat Biologics Corporation Zusuammensetzungen zur Behandlung von Krebs mittels Viren
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
EP0808364B1 (de) * 1995-02-10 2005-11-30 The Regents of the University of California Menschliche pancreas zellinien: entwicklungen und anwendungen
CA2213439A1 (en) * 1995-02-24 1996-08-29 The Trustees Of The University Of Pennsylvania Methods and compositions for administering gene therapy vectors
ATE371372T1 (de) * 1997-10-09 2007-09-15 Wellstat Biologics Corp Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren

Also Published As

Publication number Publication date
JP2013213058A (ja) 2013-10-17
EP1032269A4 (de) 2001-09-19
IL135507A0 (en) 2001-05-20
HK1028935A1 (en) 2001-03-16
HUP0003911A2 (hu) 2001-02-28
EP1032269B1 (de) 2007-08-29
CN1281336A (zh) 2001-01-24
CA2305269A1 (en) 1999-04-22
NZ518945A (en) 2007-03-30
CA2305269C (en) 2012-07-03
JP2009161558A (ja) 2009-07-23
NZ550147A (en) 2008-09-26
NZ503664A (en) 2002-08-28
WO1999018799A1 (en) 1999-04-22
EP1905304A2 (de) 2008-04-02
HUP0003911A3 (en) 2007-11-28
DE69838340T2 (de) 2008-05-21
EP1905304A3 (de) 2008-08-13
CN101618049A (zh) 2010-01-06
JP2001519175A (ja) 2001-10-23
ATE371372T1 (de) 2007-09-15
AU9603898A (en) 1999-05-03
ES2292207T3 (es) 2008-03-01
EP1032269A1 (de) 2000-09-06
NZ553508A (en) 2008-11-28

Similar Documents

Publication Publication Date Title
DE69838340D1 (de) Behandlung von neoplasmen mit interferon-empfindlichen, klonalen viren
MXPA01010393A (es) Tratamiento de neoplasmas con virus.
ATE409043T1 (de) Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von krebs des zentralen nervensystems
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
NO307968B1 (no) Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav
CY1105475T1 (el) Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
MA21687A1 (fr) Traitement du cuir avec des coplymeres amphiphiles choisis.
FR2718037B1 (fr) Appareil de traitement de tumeur.
DE60233265D1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ATE402713T1 (de) Genetisch manipulierte herpesviren zur behandlung von tumoren
ATE306281T1 (de) Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
ATE500830T1 (de) Behandlung von krebs beim menschen mit et743
ATE298339T1 (de) ß3,7-DIAZABICYCLO(3.3.0)OCTANE UND DEREN VERWENDUNG BEI DER BEHANDLUNG VON HERZRHYTHMUSSTÖRUNGENß
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE3686688D1 (de) Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten.
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.
DE58903550D1 (de) Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen.
DE69813354D1 (de) Mittel zur Behandlung von Herzkrankheiten
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
DE69803303D1 (de) Verwendung von endipalen zur behandlung von schuppenflechte
BR0012380A (pt) 2-amino-benzoxazinonas para o tratamento de vìrus do herpes simples
RU97113660A (ru) Способ лечения детей, больных вторичным панкреатитом

Legal Events

Date Code Title Description
8363 Opposition against the patent